From DingTalk VP to Femtech Pioneer: Building a Closed-Loop Home-Based Women's Health Testing Platform with Microsampling and Superior User Experience

In the past two years, the trend of at-home testing has become increasingly pronounced. In vitro diagnostic tests, once confined to professional medical institutions and healthcare providers, are now expanding into home settings and becoming accessible to the general public.

Home-based testing refers to a model where users do not need to visit medical institutions, avoiding long-distance travel and prolonged waiting times for sample collection and testing by physicians. Instead, they can independently complete the entire process of sample collection, testing, and result retrieval at home; alternatively, they may perform sample collection at home and mail the specimens to a laboratory, accessing the test results remotely.

The “Healthy China 2030” Planning Outline points out that the focus should shift from “disease treatment-centered” to “health promotion-centered.” China is entering an era of universal health, with rapidly growing attention to home-based testing, and many in vitro diagnostic companies have begun to lay out related businesses.

However, most in vitro diagnostic (IVD) companies are more adept at engaging with hospitals and physicians. In the home-testing sector, they often find themselves ill-equipped to address key challenges, such as gaining insights into users’ true needs, ensuring a positive user experience, and establishing effective, end-to-end communication channels targeted at consumers.

And these thorny issues are often readily resolved by internet professionals who have long been cultivating the consumer-facing (C-end) market.The Trend of At-Home Testing Provides a Breakthrough for Internet Talent to Enter the Professional Medical Field.Building a team with professional technical capabilities and an internet DNA has become crucial in the field of at-home testing.

Wang Qiangyu previously served as Vice President of DingTalk and is the founder of the short-video app “Qupai” and the social product Real Ruwo. He has extensive experience in the internet industry. Wang has long held a strong interest in the healthcare sector. He has observed that Chinese residents’ health awareness, along with e-commerce, logistics, and third-party medical testing services, have all reached new heights, creating new opportunities for at-home testing.

Therefore, in 2021, Wang Qiangyu co-founded Testing OneLife together with a scientist boasting 30 years of experience in the in vitro diagnostics (IVD) field. With women’s health as its entry point, the company is committed to providing professional, convenient, and scientifically grounded at-home health management solutions for women.

China's female health management market has grown year by year. According to Frost & Sullivan statistics, the market size of female health management platforms increased from RMB 510 million in 2013 to RMB 13.0 billion in 2018, with a compound annual growth rate (CAGR) of 91.3%, and is projected to reach RMB 47.17 billion by 2024.

Women are the true health hubs of their families, demonstrating high engagement in health management and influencing other household members’ choices of health management products. Therefore, Testing OneLife has chosen to rapidly enter the home testing market by focusing on women’s health management.

The healthcare sector has always prioritized outcomes over user experience. However, after years in the internet industry, Wang Qiangyu believes thatFor women's health at-home testing products, user experience should be the top priority.。

Currently, a large number of home testing products are based on saliva and stool samples. On one hand, the number of detectable indicators is limited; on the other hand, these tests have high requirements for sample quality. The sampling process is not yet simple enough for users, leaving significant room for improvement in user experience. Blood samples contain rich information and allow for the detection of numerous indicators. However, due to the complexity of venous blood collection, users are unable to perform this procedure themselves, which has prevented the widespread application of blood samples in home testing.

“Blood glucose monitoring is one of the most successful home-testing products. Only if other tests can be performed rapidly and conveniently using capillary blood, similar to blood glucose monitoring, will the home-testing sector truly experience explosive growth.”

From the perspective of optimizing user experience, the Chief Scientist of Testing OneLife, leveraging over 30 years of extensive experience in the field of in vitro diagnostics, has successfully developedIntegrated Device for Peripheral Blood Collection, eliminating the need for cumbersome venous blood collection, usersPrecise, quantitative, and convenient capillary blood collection in just a few minutes, and it ensures the safety and reliability of long-term sample transport at ambient temperature, enabling precise detection of multiple indicators. The greatest highlight of this device is its simple sampling process while still guaranteeing the safety and accuracy of testing.

Preliminary test results indicate that Testing OneLife’s developedThe test results from eluted dried blood spots prepared from capillary blood were largely consistent with those from venous plasma, with correlations for all parameters exceeding 0.93.Clinical validation is currently underway on 1,000 samples.

“The reporting phase is another area where user experience urgently needs improvement. Users often struggle to understand the professional data and terminology in their reports. We aim to provide users with easy-to-understand reports that clearly outline their health risks, guide them on how to address or avoid these risks, and offer visualized monitoring data of their endocrine indicators through charts. This constitutes an online, long-term, and visualized digital health service,” said Wang Qiangyu.

Wang Qiangyu stated, “We have observed that the female health sector primarily focuses on HPV, cervical cancer, and breast cancer, while awareness and emphasis on ovarian and endocrine health remain insufficient, with a notable lack of related products in the market.”

Therefore, Testing OneLife primarilyFocusing on Unmet Needs in Women’s Endocrine and Ovarian Health, conduct tests for the six reproductive hormones and AMH (Anti-Müllerian Hormone), providing gold-standard fertility assessments, evaluation of premature ovarian insufficiency, and regular monitoring of fertility-related indicators.

Furthermore, Testing OneLife has independently established its own laboratory, possessing capabilities in medical testing and technological R&D iteration. In the future, it can upgrade home-based blood sampling methods to enable testing for a broader range of indicators, including vitamins, thyroid function, fungal infections, HPV, cardiovascular and cerebrovascular diseases, liver function, and kidney function.

Closed-loop service is the core of the home-based testing model. "Users are highly concerned about how to proceed with intervention and management after receiving their test results. Therefore, Testing OneLife does not merely sell home-based testing products, but ratherBuilding a Closed-Loop System for At-Home Women’s Health Testing and Digital Health Management, providing services such as online interpretation of test results, professional physician report review and consultation, health indicator management and alerts, as well as professional science popularization and education, to create an intelligent, digital health management platform for users.”

When asked whether its services would compete with hospital testing, Wang Qiangyu stated that Testing OneLife focuses on health risk screening, which can alleviate the strain on hospital medical resources, increase the time available for communication between patients and doctors, and thereby enhance the overall patient experience at hospitals. Additionally, providing post-visit health management for patients—such as digital interventions, management, and follow-up in areas like exercise, diet, and lifestyle habits—is also a crucial component in improving outcomes for endocrine-related diseases.

The COVID-19 pandemic has deepened public understanding of in vitro diagnostics, particularly molecular testing. With growing health self-management awareness among individuals, home-based testing has played a pivotal role in overseas pandemic control. It is believed that home testing will undergo rapid development in the future, becoming more refined and intelligent, with an increasing number of test items shifting from hospitals to households.“It is expected that thousands of indicators will be available for home testing in the future.”

Moving forward, Testing OneLife will extensively collaborate with physicians and internet social media platforms to accelerate the adoption of at-home women’s health testing products. In the future, the company will expand its focus beyond women to serve broader populations, addressing the home-based health management needs of children, men, and the elderly. By leveraging the power of the internet, Testing OneLife aims to extend medical and healthcare services to more regions and populations, supporting the Healthy China strategy. Meanwhile, the company strives to establish itself as a leading brand in China for internet-enabled at-home health testing and health management, providing health testing and management services to 100 million female users across the country.